Immunocellular OTC Stock Financials

IMUC -  USA Stock  

USD 0.55  0.07  11.29%

Understanding current and past Immunocellular Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Immunocellular Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Immunocellular Therapeutics' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Immunocellular Therapeutics' financials over time to get the whole picture.
.
We strongly advise to harness Immunocellular Therapeutics analysis to find out if markets are presently mispricing the company. We are able to break down and analyze data for twenty-eight available reported financial drivers for Immunocellular Therapeutics, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Immunocellular Therapeutics financials, including its net income, earnings per share, current liabilities, as well as the relationship between the current ratio and total asset . As Immunocellular Therapeutics is a penny stock we also advise to confirm its price to sales numbers. Use Immunocellular Therapeutics to protect your portfolios against small market fluctuations. The stock experiences a very speculative downward sentiment. The market maybe over-reacting. Check odds of Immunocellular Therapeutics to be traded at $0.5225 in 90 days.

Immunocellular Fundamentals 

 
Refresh
With this module, you can analyze Immunocellular financials for your investing period. You should be able to track the changes in Immunocellular Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  Chance Of Financial Distress
Over 76
Immunocellular Therapeutics has more than 76 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Immunocellular Therapeutics otc stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Immunocellular Therapeutics' official financial statements usually reflect Immunocellular Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Immunocellular Therapeutics. For example, before you start analyzing numbers published by Immunocellular accountants, it's critical to develop an understanding of what Immunocellular Therapeutics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Immunocellular Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunocellular Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Immunocellular Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunocellular Therapeutics. Please utilize our Beneish M Score to check the likelihood of Immunocellular Therapeutics' management to manipulate its earnings.

Immunocellular Therapeutics Company Summary

Immunocellular Therapeutics competes with Wuxi Biologics, Ginkgo Bioworks, Csl, Biontech, and Csl. ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
InstrumentUSA OTC Stock View All
ExchangeOTC Exchange
Business Address30721 Russell Ranch
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.imuc.com
Phone818 264 2300
CurrencyUSD - US Dollar

Immunocellular Therapeutics Key Financial Ratios

Generally speaking, Immunocellular Therapeutics' financial ratios allow both analysts and investors to convert raw data from Immunocellular Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Immunocellular Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Immunocellular Therapeutics reports annually and quarterly.

Immunocellular Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immunocellular Therapeutics's current stock value. Our valuation model uses many indicators to compare Immunocellular Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunocellular Therapeutics competition to find correlations between indicators driving Immunocellular Therapeutics's intrinsic value. More Info.
Immunocellular Therapeutics is rated fourth overall in number of shares shorted category among related companies. It is rated below average in net income category among related companies .

Immunocellular Therapeutics Systematic Risk

Immunocellular Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Immunocellular Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was sixty with a total number of output elements of one. The Beta measures systematic risk based on how returns on Immunocellular Therapeutics correlated with the market. If Beta is less than 0 Immunocellular Therapeutics generally moves in the opposite direction as compared to the market. If Immunocellular Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Immunocellular Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Immunocellular Therapeutics is generally in the same direction as the market. If Beta > 1 Immunocellular Therapeutics moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Immunocellular Therapeutics Financials

What exactly are Immunocellular Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Immunocellular Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Immunocellular Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Immunocellular Therapeutics investors may use each financial statement separately, they are all related. The changes in Immunocellular Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunocellular Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Immunocellular Therapeutics October 21, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Immunocellular Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Immunocellular Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immunocellular Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Immunocellular OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immunocellular Therapeutics's daily price indicators and compare them against related drivers.
Downside Deviation16.24
Information Ratio0.0957
Maximum Drawdown127.67
Value At Risk(21.67)
Potential Upside33.33
Please see Risk vs Return Analysis. Note that the Immunocellular Therapeutics information on this page should be used as a complementary analysis to other Immunocellular Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Immunocellular OTC Stock analysis

When running Immunocellular Therapeutics price analysis, check to measure Immunocellular Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocellular Therapeutics is operating at the current time. Most of Immunocellular Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immunocellular Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunocellular Therapeutics' price. Additionally, you may evaluate how the addition of Immunocellular Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
The market value of Immunocellular Therapeutics is measured differently than its book value, which is the value of Immunocellular that is recorded on the company's balance sheet. Investors also form their own opinion of Immunocellular Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immunocellular Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunocellular Therapeutics' market value can be influenced by many factors that don't directly affect Immunocellular Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunocellular Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunocellular Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunocellular Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.